GSK Gears Up for Q1 Earnings: Here's What to Expect [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Factors to Note GSK reports financial figures under three segments — Specialty Medicines, Vaccines and General Medicines. Our model estimate for the company's total revenues is pegged at £7.36 billion ($9.12 billion). In the first quarter, higher sales of newer products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix are likely to have offset the decline in sales of older HIV drugs and respiratory medicines due to generic erosion and competitive pressure. Our model suggests the Respiratory sales to be around £1.81 billion for the quarter. In HIV, the strong sales growth trend witnessed in recent quarters of the two-drug regimens, Juluca and Dovato and long-acting regimens, Cabenuva and Apretude, might have partially offset losses in sales of the three-drug regimens during the to-be-reported quarter. Our model estimates sales from the HIV portfolio to be £1.57 billion for the quarter. Sales of COPD inhalers Trelegy Ellipta, Breo Ellipta and Anoro Ellipta ar
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health [Yahoo! Finance]Yahoo! Finance
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global HealthBusiness Wire
- Sarepta Elevidys accelerated approval criticized by ICER exec [Seeking Alpha]Seeking Alpha
- Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.MarketBeat
SRPT
Earnings
- 5/1/24 - Beat
SRPT
Sec Filings
- 5/1/24 - Form 10-Q
- 4/24/24 - Form DEF
- 4/24/24 - Form ARS
- SRPT's page on the SEC website